Первая пятница декабря
Конгресс 2014
Главная / Новости


3 4 5 6 7 8 9 10 11 12

23 февраля 2018 - Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein.

19 февраля 2018 - Emerging Novel Delivery Systems for Ocular Infections
Ocular infections, such as acute bacterial keratitis and postoperative endophthalmitis, can cause rapid, significant, and permanent visual impairment. Successful management requires early diagnosis, in addition to the correct antibiotic choice administered at appropriate therapeutic levels for the optimum duration, to eradicate the causative organism. This CME activity will discuss emerging delivery systems in the management of ocular infections.

18 февраля 2018 - Macular Vessel Density in Glaucomatous Eyes with Focal Lamina Cribrosa Defects
Macular Vessel Density in Glaucomatous Eyes with Focal Lamina Cribrosa Defects Ghahari, Elham MD*; Bowd, Christopher PHD*; Zangwill, Linda M. PHD*; Suh, Min Hee MD*,†; Shoji, Takuhei MD, PHD*,‡; Hasenstab, Kyle A. PHD*; Saunders, Luke J. PHD*; Moghimi, Sasan MD*; Hou, Huiyuan MD, PHD*; Manalastas, Patricia Isabel C. MD*; Penteado, Rafaella C. MD*; Weinreb, Robert N. MD* Journal of Glaucoma: February 16, 2018 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/IJG.0000000000000922 Original Study: PDF Only

17 февраля 2018 - Scleral Buckling 101
We might be in the age of vitrectomy, but we believe that scleral buckling is the treatment of choice for certain retinal detachments But which patients are the best candidates for a primary scleral buckle and how should surgery be approached? We overview when primary buckling should be considered and provide guidance on which techniques will help success, as well as when to avoid a primary buckle Welcome to scleral buckling 101 for the senior ophthalmology resident and the junior retina fellow!

16 февраля 2018 - Весеннее заседание группы молодых ученых Научный Авангард
Информация и программа размещены на сайте

13 февраля 2018 - A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
Mahmoud A Khaimi Dean McGee Eye Institute, Oklahoma City, OK, USA Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty. Methods: This was a retrospective medical chart review conducted at a single US center. Data were collected on patients with glaucoma who underwent canaloplasty with or without cataract surgery, and were prescribed LE suspension 0.5% postoperatively. Outcomes evaluated included postsurgical inflammation (anterior chamber [AC] cells and flare), intraocular pressure (IOP), number of IOP-lowering medications, and postsurgical complications. Results: Data were collected on 204 patients (262 eyes) with a mean (SD) age of 71.6 (11.3) years. The most frequent LE dosing regimens at day 1, week 1, and month 1 postsurgery were QID (92.3%; 241/261), TID (52.6%; 133/253), and QD (65.5%; 78/119), respectively. Inflammation (AC flare and cells), mostly mild, was noted in 33.2% (86/259) of eyes on postoperative day 1 and 8.6% (21/244) of eyes at month 1. Mean IOP and mean number of IOP-lowering medications were significantly reduced from baseline (P<0.001) at all time points postoperatively. Complete (no IOP-lowering medication) or qualified (use of ≤2 IOP-lowering medications) surgical success was achieved in 78.8% and 90.6% of eyes, respectively, at month 6 and 63.4% and 92.7% of eyes at month 36. The most frequently observed postoperative complication was hyphema in 48.7% (126/259) eyes at day 1, which decreased to 0.4% (1/244) of eyes by month 1. IOP ≥30 mmHg was noted in 13 (5.3%) eyes at postoperative week 1 and rarely thereafter, and no patient discontinued therapy because of an IOP increase. Conclusion: These real-world data suggest that canaloplasty with or without cataract surgery managed postoperatively with LE suspension 0.5% is effective and safe in the glaucoma patient.

08 февраля 2018 - Синусоидальная трифокальная ИОЛ! Первая и единственная!
AcrivaUD Trinova is manufactured with Seamless Vision Technology (SVT) that is invented by VSY Biotechnology. The SVT is a unique patent pending technique to produce an IOL optical surface which does not exhibit any sharp edges. It provides best optical performance in trifocal IOL design. The lens shape is derived from sinusoidal functions and results in smoothly varying surface profiles. Therefore ideal continuous vision is achieved as opposed to common traditional overlapping diffraction pattern trifocal IOLs with sharp edges. This concept also helps to reduce halos and scattered light.

07 февраля 2018 - Про ПАНОПТИК (ИОЛ)
PanOptix™ was launched in September 2015 – in the years since, how has this multifocal IOL performed in the clinic? Download the PDF to see what has been accomplished

02 февраля 2018 - The Khmer Sight Foundation: helping to deliver and develop eyecare programs to a country in serious need
At a Glance Cambodia has a small population of 15 million, but there are only 32 ophthalmologists – and only 23 who are surgically trained The incidence of blindness is high and on the increase, despite 90 percent of all cases being preventable The Khmer Sight Foundation (KSF) was initiated to bring eyecare to Cambodians who need it most Here, we share the story of the first mission, and look to the future of KSF – and preserving the sight of the Cambodian population.

01 февраля 2018 - Готовь плавки зимой) 13th EGS Congress, Florence 2018 (май)
Приглашение Президента на Конгресс! Будет хорошо!

30 января 2018 - Лидеры всемирной глаукомной ассоциации поменялись... Leadership changes
Кто говорит, что ротация это плохо? 2018 starts with welcoming a new WGA President: Keith Martin, Professor and Head of Ophthalmology, University of Cambridge, UK. The new President Elect is Fabian Lerner, Professor of Ophthalmology, University Favaloro School of Medical Sciences in Buenos Aires, Argentina. At the Executive Office we welcome Shan Lin, Professor of Clinical Ophthalmology at the University of California, San Francisco, US as Executive Vice President and Kaweh Mansouri, Consultant at the Glaucoma Center, Montchoisi Clinic, Lausanne, Switzerland as Associate Executive Vice President. New members of the WGA Board of Governors per 2018 are Arthur Sit (Rochester, Minnesota United States), Ingeborg Stalmans (Leuven, Belgium), Fotis Topouzis (Thessaloniki, Greece) and Lingam Vijaya (Chennai, India).

29 января 2018 - Patients’ Treatment Preferences For most patients, starting an eye drop is the simplest first step. By Atalie C. Thompson, MD, MPH, and Kelly W. Muir, MD, MHS
When patients receive a new diagnosis of glaucoma, they suddenly face the numerous, complex trade-offs in risks and benefits posed by the three main options for therapy—medications, laser surgery, and incisional surgery. For a majority of patients, starting a topical glaucoma medication is the most intuitive first step of treatment. The practice of instilling eye drops may be familiar if they wear contact lenses or have administered topical ophthalmic solutions for dry eye disease or allergic conjunctivitis. Moreover, for many of them, daily medication use is already a part of their routine.

28 января 2018 - Uniting Over 500 Leaders in the Development of Ground-Breaking Ophthalmic Technologies
Апрель, похоже, будет насыщенным!

26 января 2018 - Successful Outcomes With the Xen Gel Stent
Clinical Minute distills a peer-reviewed study into what is relevant for practicing clinicians/surgeons in approximately one minute. In the debut episode of this series, Neda Shamie, MD, outlines a recent paper by Iqbal Ike K. Ahmed, MD, FRCSC, on the Xen implant (Allergan). The paper offers surgical pearls and patient management protocols to ensure successful outcomes with this microinvasive glaucoma surgical device.

25 января 2018 - Pharmacogenomics and Personalized Medicine. "Персональная" медицина
What is the advantage to you of publishing in Pharmacogenomics and Personalized Medicine? It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website. Although Pharmacogenomics and Personalized Medicine receives many papers, unlike most traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish. The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Pharmacogenomics and Personalized Medicine has a quicker turnaround time than this. Generally peer review is complete within 4-7 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 9 weeks for a final decision. Many authors have found that our peer reviewer’s comments substantially add to their final papers.

23 января 2018 - Наши Турецкие коллеги приглашают на "живую" хирургию в конце марта!
Присоединяйтесь. Или смотри онлайн

3 4 5 6 7 8 9 10 11 12
Что "заставляет" Вас заниматься научными исследованиями?